Home/Pipeline/KRP-209

KRP-209

Idiopathic Pulmonary Fibrosis (IPF)

Phase IIActive

Key Facts

Indication

Idiopathic Pulmonary Fibrosis (IPF)

Phase

Phase II

Status

Active

Company

Kissei Pharmaceutical

About Kissei Pharmaceutical

Kissei Pharmaceutical's mission is to contribute to global healthcare by developing and providing innovative, high-quality pharmaceutical products. The company has achieved a strong market position in Japan through its established expertise in urology and nephrology, supported by a portfolio of marketed products and a promising late-stage pipeline. Its strategy centers on deepening its specialization in core therapeutic areas while expanding its global footprint through strategic in-licensing and co-development partnerships. With a market capitalization of approximately $193.58 billion, Kissei possesses the financial strength to advance its R&D ambitions and pursue strategic opportunities.

View full company profile

Therapeutic Areas

Urology Nephrology Metabolic Disorders Gastrointestinal Rare Diseases

Other Idiopathic Pulmonary Fibrosis (IPF) Drugs

Drug	Company	Phase	Status
OATD-01	Molecure	Phase II	Active, recruiting
FP-020 (BMS-986235)	Foresee Pharmaceuticals	Phase 2	Active
Buloxibutid (C21)	Vicore Pharma	Phase 2b	Active, Now Enrolling
AP02	Avalyn Pharmaceuticals	Phase 2	Active
Gento-Fibrose Pulmonaire Program	Genoscience Pharma	Preclinical	Active
SM001 (alidornase/Tigerase)	SarcoMed USA	Research	Active
NLM-001	Nelum Pharma	Phase 1	Active
GNS-3545 (ROCK2 Inhibitor)	Genosco	Phase 1	Active
TG2 Inhibitor Program	Isterian Biotech	Preclinical	Active
Taladegib (ENV-101)	Endeavor BioMedicines	Phase 2b	Active
CAL101	Calluna Pharma	Phase 2	Active
NVP-13	Velvio	Pre-clinical	Active